Pediatric Diabetes,
Год журнала:
2022,
Номер
23(8), С. 1297 - 1321
Опубликована: Дек. 1, 2022
The
author
declares
that
there
is
no
conflict
of
interest.
peer
review
history
for
this
article
available
at
https://publons.com/publon/10.1111/pedi.13429.
There
original
data
linked
to
guideline.
Frontiers in Endocrinology,
Год журнала:
2021,
Номер
12
Опубликована: Сен. 13, 2021
Diabetes
is
a
complex
disease
that
affects
over
400
million
people
worldwide.
The
life-long
insulin
injections
and
continuous
blood
glucose
monitoring
required
in
type
1
diabetes
(T1D)
represent
tremendous
clinical
economic
burdens
urges
the
need
for
medical
solution.
Pancreatic
islet
transplantation
holds
great
promise
treatment
of
T1D;
however,
difficulty
regulating
post-transplantation
immune
reactions
to
avoid
both
allogenic
autoimmune
graft
rejection
bottleneck
field
transplantation.
Cell
replacement
strategies
have
been
performed
hepatic,
intramuscular,
omentum,
subcutaneous
sites,
animal
models
human
patients.
However
more
optimal
sites
methods
improving
survival
are
needed
successfully
translate
these
studies
relevant
therapy.
In
this
review,
we
summarize
current
progress
as
well
transplantation,
including
stem
cell-derived
functional
islets.
We
also
discuss
contribution
cells,
vessel
formation,
extracellular
matrix,
nutritional
supply
on
survival.
Developing
new
with
emerging
technologies
improve
simplify
regulation
will
greatly
benefit
future
success
cell
therapy
diabetes.
The Journal of Clinical Endocrinology & Metabolism,
Год журнала:
2023,
Номер
108(7), С. 1614 - 1623
Опубликована: Фев. 3, 2023
Diabetes
technologies
represent
a
paradigm
shift
in
type
1
diabetes
care.
Continuous
subcutaneous
insulin
infusion
(CSII)
pumps
and
continuous
glucose
monitors
(CGM)
improve
glycated
hemoglobin
(HbA1c)
levels,
enhance
time
optimal
glycemic
range,
limit
severe
hypoglycemia,
reduce
distress.
The
artificial
pancreas
or
closed-loop
system
connects
these
devices
via
control
algorithm
programmed
to
maintain
target
glucose,
partially
relieving
the
person
living
with
of
this
constant
responsibility.
Automating
delivery
reduces
input
required
from
those
wearing
device,
leading
better
physiological
psychosocial
outcomes.
Hybrid
therapy
systems,
requiring
user-initiated
prandial
doses,
are
most
advanced
systems
commercially
available.
Fully
no
boluses,
dual
hormone
have
been
shown
be
safe
efficacious
research
setting.
Clinical
adoption
remains
early
stages
despite
recent
technological
advances.
People
diabetes,
health
care
professionals,
regulatory
agencies
continue
navigate
complex
path
equitable
access.
We
review
available
devices,
evidence,
clinical
implications,
barriers
regarding
innovatory
technologies.
Diabetes Care,
Год журнала:
2023,
Номер
46(12), С. 2092 - 2101
Опубликована: Ноя. 27, 2023
Use
of
effective
treatments
and
management
programs
is
leading
to
longer
survival
people
with
diabetes.
This,
in
combination
obesity,
thus
contributing
a
rise
living
more
than
one
condition,
known
as
multiple
long-term
conditions
(MLTC
or
multimorbidity).
MLTC
defined
the
presence
two
conditions,
possible
combinations
physical,
infectious,
mental
health
where
no
condition
considered
index.
These
include
range
such
cardiovascular
diseases,
cancer,
chronic
kidney
disease,
arthritis,
depression,
dementia,
severe
illnesses.
has
major
implications
for
individual
poor
quality
life,
worse
outcomes,
fragmented
care,
polypharmacy,
treatment
adherence,
mortality,
significant
impact
on
care
services.
challenge,
interventions
prevention
are
lacking
robust
evidence
base.
The
key
research
directions
diabetes
from
global
perspective
system
delivery
coordination,
lifestyle
therapeutic
interventions.
Diabetes Obesity and Metabolism,
Год журнала:
2021,
Номер
23(8), С. 1942 - 1949
Опубликована: Май 9, 2021
To
evaluate
the
real-world
performance
of
MiniMed
670G
system
in
Europe,
individuals
with
diabetes.Data
uploaded
from
October
2018
to
July
2020
by
living
Europe
were
aggregated
and
retrospectively
analysed.
The
mean
glucose
management
indicator
(GMI),
percentage
time
spent
within
(TIR),
below
(TBR)
above
(TAR)
glycaemic
ranges,
use
insulin
consumed
users
10
or
more
days
sensor
data
after
initial
Auto
Mode
start
determined.
Another
analysis
based
on
suboptimally
(GMI
>
8.0%)
well-controlled
<
7.0%)
glycaemia
pre-Auto
initiation
was
also
performed.Users
(N
=
14
899)
a
81.4%
achieved
GMI
7.0%
±
0.4%,
TIR
72.0%
9.7%,
TBR
less
than
3.9
mmol/L
2.4%
2.1%
TAR
25.7%
10%,
initiating
Mode.
When
compared
initiation,
reduced
0.3%
0.4%
increased
9.6%
9.9%
(P
.0001
for
both).
Significantly
improved
control
observed
irrespective
levels
8.0%.
While
total
daily
dose
both
groups,
greater
increase
latter,
an
primarily
due
basal
delivery.
By
contrast,
decreased
slightly
users.Most
70%
7%
while
minimizing
hypoglycaemia,
environment.
These
international
consensus-met
outcomes
enabled
automated
delivery
meeting
real-time
requirements
adapted
each
individual
user.
Journal of Clinical Medicine,
Год журнала:
2021,
Номер
10(11), С. 2445 - 2445
Опубликована: Май 31, 2021
The
aim
of
this
systematic
review
and
meta-analysis
was
to
compare
time
in
range
(TIR)
(70–180
mg/dL
(3.9–10.0
mmol/L))
between
fully
closed-loop
systems
(CLS)
standard
care
(including
hybrid
systems)
during
physical
exercise
people
with
type
1
diabetes
(T1D).
A
literature
search
conducted
EMBASE,
PubMed,
Cochrane
Central
Register
Controlled
Trials,
ISI
Web
Science
from
January
1950
until
2020.
Randomized
controlled
trials
including
studies
different
CLS
were
compared
against
T1D.
performed
using
the
random
effects
model
restricted
maximum
likelihood
estimation
method.
Six
randomized
involving
153
participants
T1D
all
age
groups
included.
Due
crossover
test
designs,
included
repeatedly
(a–d)
if
or
interventions
different.
Applying
methodology
increased
comparisons
a
total
number
266
participants.
TIR
higher
an
absolute
mean
difference
(AMD)
6.18%,
95%
CI:
1.99
10.38%
favor
CLS.
In
subgroup
analysis,
AMD
9.46%,
2.48%
16.45%
children
adolescents
while
for
adults
1.07%
−0.81%
2.96%
moderately
improved
comparison
This
effect
particularly
pronounced
showing
that
use
significantly
care.
Metabolism,
Год журнала:
2024,
Номер
152, С. 155786 - 155786
Опубликована: Янв. 10, 2024
Diabetes
presents
a
pressing
healthcare
crisis,
necessitating
innovative
solutions.
Organoid
technologies
have
rapidly
advanced,
leading
to
the
emergence
of
bioengineering
islet
organoids
as
an
unlimited
source
insulin-producing
cells
for
treating
insulin-dependent
diabetes.
This
advancement
surpasses
need
cadaveric
transplantation.
However,
clinical
translation
this
approach
faces
two
major
limitations:
immature
endocrine
function
and
absence
perfusable
vasculature
compared
primary
human
islets.
In
review,
we
summarize
latest
developments
in
functional
vitro
promoting
vascularization
organoid
grafts
before
after
We
highlight
crucial
roles
ensuring
long-term
survival,
maturation,
functionality
organoids.
Additionally,
discuss
key
considerations
that
must
be
addressed
organoid-based
therapy,
including
immaturity,
undesired
heterogeneity,
potential
tumorigenic
risks.
Abstract
Type
1
diabetes
mellitus
(T1DM)
is
characterized
by
absolute
insulin
deficiency
primarily
due
to
autoimmune
destruction
of
pancreatic
β‐cells.
The
prevailing
treatment
for
T1DM
involves
daily
subcutaneous
injections,
but
a
substantial
proportion
patients
face
challenges
such
as
severe
hypoglycemic
episodes
and
poorly
controlled
hyperglycemia.
For
patients,
more
effective
therapeutic
option
the
replacement
β‐cells
through
allogeneic
transplantation
either
entire
pancreas
or
isolated
islets.
Unfortunately,
scarcity
transplantable
human
organs
has
led
growing
list
waiting
an
islet
transplant.
One
potential
alternative
xenotransplantation
porcine
However,
inter‐species
molecular
incompatibilities,
tissues
trigger
robust
immune
response
in
humans,
leading
xenograft
rejection.
Several
promising
strategies
aim
overcome
this
challenge
enhance
long‐term
survival
functionality
xenogeneic
grafts.
These
include
use
islets
derived
from
genetically
modified
pigs,
immunoisolation
encapsulation
biocompatible
materials,
creation
immunomodulatory
microenvironment
co‐transplanting
with
accessory
cells
utilizing
biomaterials.
This
review
concentrates
on
delineating
primary
obstacles
elucidates
fundamental
principles
recent
breakthroughs
aimed
at
addressing
these
challenges.
Journal of Diabetes Science and Technology,
Год журнала:
2024,
Номер
unknown
Опубликована: Ноя. 8, 2024
With
increasing
prevalence
of
obesity
and
cardiovascular
diseases,
there
is
a
growing
interest
in
the
use
glucagon-like
peptide-1
receptor
agonists
(GLP-1RAs)
as
an
adjunct
therapy
type
1
diabetes
(T1D).
The
GLP-1RAs
are
currently
not
approved
by
US
Food
Drug
Administration
for
treatment
T1D
absence
randomized
controlled
trials
documenting
efficacy
safety
these
agents
this
population.
Diabetes
Technology
Society
convened
series
three
consensus
meetings
clinicians
researchers
with
expertise
technology,
GLP-1RA
therapy,
management.
project
was
aimed
at
synthesizing
current
literature
providing
conclusions
on
to
automated
insulin
delivery
(AID)
systems
adults
T1D.
expert
panel
members
met
virtually
times
January
17,
2024,
April
24,
August
14,
discuss
topics
ranging
from
physiology
outcomes
limitations
sensors,
algorithms,
AID
systems.
panelists
also
identified
research
gaps
future
directions
research.
voted
favor
31
recommendations.
This
report
presents
opinions
participants
that,
using
systems,
have
potential
(1)
provide
effective
(2)
improve
glycemic
metabolic
without
risk
severe
hypoglycemia
or
diabetic
ketoacidosis.
Frontiers in Endocrinology,
Год журнала:
2021,
Номер
12
Опубликована: Авг. 10, 2021
Insulin
injection
is
currently
the
main
therapy
for
type
1
diabetes
(T1D)
or
late
stage
of
severe
2
(T2D).
Human
pancreatic
islet
transplantation
confers
a
significant
improvement
in
glycemic
control
and
prevents
life-threatening
hypoglycemia
T1D
patients.
However,
shortage
cadaveric
human
islets
limits
their
therapeutic
potential.
In
addition,
chronic
immunosuppression,
which
required
to
avoid
rejection
transplanted
islets,
associated
with
complications,
such
as
an
increased
risk
malignancies
infections.
Thus,
there
need
novel
approaches
large-scale
generation
functional
protected
from
autoimmune
order
ensure
durable
graft
acceptance
without
immunosuppression.
An
important
step
addressing
this
strengthen
our
understanding
transplant
immune
tolerance
mechanisms
both
rejection.
Engineering
that
can
attacks
host
cells
would
provide
alternative
safe
resource
therapy.
pluripotent
stem
(hPSCs)
offer
potentially
limitless
supply
because
self-renewal
ability
pluripotency.
Therefore,
studying
induction
hPSC-derived
will
directly
contribute
toward
goal
generating
cure
insulin-dependent
diabetes.
review,
we
discuss
current
progress
protection
cell-derived
cell
treating
